Blindness

OCT technology detects blood vessel in the eye

Research published in the Proceedings of the National Academy of Sciences (PNAS) demonstrates that technology invented by researchers at Oregon Health & Science University’s Casey Eye Institute can improve the clinical management of the leading causes of blindness. Optical coherence tomography (OCT) angiography could largely replace current dye-based angiography in the management of these diseases.

David Wilson, M.D.
David Wilson, M.D.
Source: Oregon Health & Science University

OHSU researchers found that OCT angiography has considerable advantages over conventional techniques for the diagnosis and management of macular degeneration, diabetic eye disease and glaucoma, the leading causes of blindness in the United States. “This is a significant breakthrough technology that could fundamentally change the way ophthalmologists diagnose and care for patients with retinal vascular diseases that cause blindness,” said David Wilson, M.D., Director of the OHSU Casey Eye Institute and Chair of the Department of Ophthalmology in the OHSU School of Medicine. “It will also allow us to diagnose patients earlier, permitting more timely treatment to avoid irreversible loss of vision.”

OCT angiography has been in development for several years in a few centers around the world. The key breakthrough that Yali Jia, Ph.D., study investigator and Assistant Professor of Ophthalmology at OHSU School of Medicine, OHSU Casey Eye Institute, and David Huang, M.D., Ph.D., study investigator and Peterson Professor of Ophthalmology, OHSU School of Medicine, OHSU Casey Eye Institute achieved was an algorithm called “split-spectrum amplitude-decorrelation angiography” (SSADA) that improved the quality of OCT angiography. “We worked very hard to bring this new technology to clinical use only three years after its invention,” said Dr. Jia. “We are thrilled that its initial clinical demonstrations in a number of important eye diseases could be made public in a prestigious journal such as PNAS.”

The OCT angiography used in the study is a noninvasive three-dimensional alternative to conventional angiography. It does not require injections and allows clinicians to measure vascular density and blood flow in vessels in a quantitative manner. This provides new information that is very useful for clinical diagnosis and management.

Conventional dye-based angiography produces a two-dimensional image that cannot be evaluated quantitatively. It also is an invasive procedure in which orange dye (fluorescein) is intravenously injected to illuminate the blood vessels. This procedure can cause nausea and vomiting, and, rarely anaphylaxis, which is a serious allergic reaction.

“The new OCT angiography will be much less invasive for patients. As a result, it is ideal for screening patients for disease and routine checkups to see if treatments are working,” said Dr. Huang. “I believe this technology will be used much more frequently than conventional dye-based angiography because it is faster, better, safer and cheaper. This will also surely lead to better management of eye diseases.”


Source: Oregon Health & Science University

07.05.2015

Read all latest stories

Related articles

Photo

Snake venom helps hydrogels stop the bleeding

A nanofiber hydrogel infused with snake venom may be the best material to stop bleeding quickly, according to Rice University scientists.

Photo

Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Photo

Analysing molecular composition

Infrared light is key in novel blood test

A new study carried out by a team of laser physicists, molecular biologists and physicians based at LMU Munich and the Max Planck Institute for Quantum Optics has confirmed the temporal stability of…

Related products

Greiner – VACUETTE FC Mix tube

Blood Glucose

Greiner – VACUETTE FC Mix tube

Greiner Bio-One
Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
Analyticon Biotechnologies AG - Urilyzer 100 Pro

Urinalysis

Analyticon Biotechnologies AG - Urilyzer 100 Pro

Analyticon Biotechnologies AG
Analyticon Biotechnologogies – Hemolyzer 3 NG / Hemolyzer 5 NG

Blood Cell Counter

Analyticon Biotechnologogies – Hemolyzer 3 NG / Hemolyzer 5 NG

Analyticon Biotechnologies AG
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
Subscribe to Newsletter